Policy for Expanded Access to Investigational Medicines

Inhibrx is committed to discovering and developing new, innovative therapies for people with life-threatening conditions. Toward this goal, we have developed a diverse pipeline of therapeutic candidates specifically designed to leverage the power of our core single-domain antibody platform and protein-engineering expertise. Our goal is to conduct our clinical trials as quickly as possible, in order to obtain marketing authorization for our therapeutic candidates from the U.S. Food and Drug Administration (FDA) and other regulatory agencies to ensure wider patient access.

During the investigational phase of drug development, access to experimental therapies is primarily through the clinical trial investigators, who are registered and trained to conduct clinical research following strict clinical protocols and guidelines. For a list of our clinical trials and research locations, please click on our website tab labeled "PATIENTS," which includes links to the www.clinicaltrials.gov registry. Investigational clinical research following FDA authorized clinical protocols is key to fully understanding safety and efficacy of our therapeutic candidates prior to making them widely available to patients. We encourage all patients who may be eligible for one of our clinical trials to speak with their physicians about the possibility of participating in these clinical trials, both to obtain access to one of our investigational therapeutic candidates and also to support the development of these promising new therapies.

Expanded Access, also known as Compassionate Use, refers to the use of an investigational therapeutic candidate that has not yet been approved by the FDA to treat or prevent a serious disease or condition. Providing an investigational therapeutic candidate as part of an Expanded Access Program is a complex matter and is different from studying the investigational therapeutic candidate as part of a clinical trial, where more comprehensive safety and efficacy data are collected. We understand the need for Expanded Access Programs under certain circumstances, and we recognize the importance of each clinical trial sponsor thoughtfully considering all the issues and having an appropriate policy in place. At this time, access to our INBRX-109 therapeutic candidate, and our other investigational medicines, is not available outside of enrollment in one of our clinical trials. However, we are aware of a potential medical need and accordingly, we will re-evaluate the status of this policy periodically and may revise it at any time.

Anyone with questions about this Expanded Access Policy, including any licensed physicians who believe a patient may benefit from an Inhibrx investigational therapeutic candidate, may contact Inhibrx at medinfo@inhibrx.com. This mailbox will be regularly reviewed on a weekly basis, and we will use our best efforts to acknowledge each inquiry within 3 business days. In the U.S., physicians may find additional information regarding Expanded Access to investigational therapies by visiting https://www.fda.gov/news-events/expanded-access/expanded-access-information-physicians.